In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

HFA Cardio Talk

Available on your favourite apps

December 2022

Emerging key role of patients profiling in heart failure patients management

Dr. Francesca Musella
Naples, IT


Dra. Brenda Moura_2.jpg

Dr. Brenda Moura
Porto, PT


In December´s HFA Cardio Talk, Dr. Francesca Musella interviews Dr. Brenda Moura on the emerging role of patients´profiling in Heart Failure. The podcast starts with an overview of this emerging concept introduced by current HF guidelines, and then addresses the main benefits and practical repercussions of following this approach in clinical practice. In conclusion, the podcast underlies how tailoring HF medications prescription to each patient specific profile and personal tolerability may guide physicians to both HF medications prescription and up-tritation in real world scenarios.


November 2022

Valvular heart disease in patients with heart failure
Head photo tomasoni.jpg

Dr. Daniela Tomasoni 
Brescia, IT


Head photo Adamo.jpg

Dr. Marianna Adamo
Brescia, IT


In November’s HFA Cardio Talk, Dr. Daniela Tomasoni interviews Dr.Marianna Adamo on valvular heart disease in heart failure. The podcast starts with an epidemiological overview and then addresses the main pathophysiological mechanisms of valvular heart disease in patients with heart failure. It also discusses current recommendations regarding the treatment of mitral regurgitation. In conclusion, dr. Adamo will guide us through the new available percutaneous devices for the treatment of tricuspid regurgitation.

October 2022

The changing role of Cardiovascular Magnetic Resonance in Heart Failure patients
Jessica Artico photo.jpg

Dr. Jessica Artico
London, UK


Chiara Bucciarelli Ducci photo.jpeg

Prof. Chiara Bucciarelli-Ducci 
London, UK


In October’s HFA Cardio Talk, Prof Chiara Bucciarelli-Ducci, interviewed by Dr Jessica Artico, will discuss the enhanced role of Cardiovascular Magnetic Resonance in Heart Failure Patients and in the new HF guidelines.  It will walk us through the advancements of this imaging technique, what can possibly change after the results of recent HF trials, as well as the role of stress CMR and the future perspectives of CMR for a HF specialist. 

September 2022

Lived Experiences of Dyads with a Left Ventricular Assist Device: Lessons Learned for Around the World
A. Massouh.jpg

Dr. Angela Massouh  
Beirut, Lebanon



Dr. Loreena Hill
Belfast, Ireland


In September’s HFA Cardio Talk, Dr. Angela Massouh interviews Dr. Loreena Hill on living with a left ventricular assist device, and lessons learned from around the globe. This podcast addresses the experiences of patients living with a left ventricular assist device and their informal caregivers. It will also highlight clinical aspects of self-care and how international multidisciplinary healthcare providers can do better to assist this vulnerable group.

July 2022

Gene Editing: Paving the way to end the burden of inherited cardiomyopathies or just a useful research tool?
Emma Robinson.jpg

Dr. Emma Louise Robinson
Aurora, Colorado, U.S



Prof. Luisa Mestroni 
Aurora, Colorado, U.S


In July’s HFA Cardio Talk podcast, Dr Emma Robinson interviews Prof Luisa Mestroni, Director of the International Familial Cardiomyopathy Registry and Co-Director of the Molecular Genetics Program of the Cardiovascular Institute in Denver. This podcast discusses current approaches to diagnosis, treatment options and support for patients and families of inherited cardiomyopathy as well as how advances in gene editing have transformed translational research, understanding of disease mechanisms and prospects for clinical care.

June 2022

HFpEF – The enigma of Heart Failure

Assist. Prof. Markus Wallner
Graz, Austria



Prof. Rudolf de Boer
Groningen, the Netherlands


This podcast will discuss the most recent developments in heart failure with preserved ejection fraction (HFpEF). Prof. de Boer, HFA board member and HFpEF expert, is interviewed by Dr. Wallner, chair of the HFA Young Committee, and will walk us through the diagnostic and therapeutic challenges of HFpEF and provide tips and tricks for the management of patients with HFpEF.

May 2022

Insights and prospects from the Heart Failure Congress 2022, Madrid, Spain
A. Cannata.jpg

Dr. Antonio Cannata
London, UK



Dr. Mateusz Sokolski,
Wrocław, Poland



Dr. Otilia Țica
Oradea, Romania



Prof. Finn Gustafsson
Copenhagen, Denmark


John Cleland_photo.png

Prof. John Cleland
London, UK



Prof Theresa McDonagh
London, UK



Prof. Gianluigi Savarese
Stockholm, Sweden


Carolyn Lam_PIC.jpeg

Prof Carolyn Lam


Marco Metra.jpg

Prof. Marco Metra
Brescia, Italy


This podcast will discuss the insights and highlights shared by key-leaders in heart failure during the annual meeting: Heart Failure Congress, held in Madrid, Spain. Prof. Gustafson offers an overview on advanced heart failure therapies and the role of MCS (mechanical circulatory support). Prof Cleland debates when should we attempt revascularisation in heart failure patients. Prof McDonagh shares the updates and changes in the implementation of the HF guidelines in the last year, since their release. Prof Savarese highlights the best scientific statement of this year, the universal definition of Heart Failure. Prof Lam provides key message and trials in HF and also underlines the sex-differences in these patients. Prof Metra discusses the pillars and future perspectives of HF and the importance of education.

April 2022

Tips and tricks in interpretation of clinical trials
Petar Seferovic.jpg

Prof. Petar M. Seferović
Belgrade, Serbia



Dr. Ivan Milinković
Belgrade, Serbia


The podcast discusses how major clinical trials changed the perspective on how randomized clinical trials are designed, conducted and interpreted. It gives the insight into major positive and negative aspects of the clinical trials, which results influenced the contemporary heart failure treatment

March 2022

Implementing the use of HF treatments in clinical practice

Prof. Gianluigi Savaresse
Stockholm, Sweden


Otilia Tica.jpg

Dr. Otilia Țica
Oradea, Romania 


This podcast will discuss the optimal implementation of heart failure therapies: guidelines, and challenges. It tackled how registries support implementation of care and trial design in heart failure. Prof. Gianluigi Savaresse interviewed by Dr Otilia Țica, member of HFA Young committee, will guide us throughout the challenges of implementing optimal therapies in HF and will offer an insight on how registries can help directly improve quality of care.


February 2022

The SGLT2-inhibitors revolution in Heart Failure. Current indications and future perspectives

Giuseppe Rosano
London, UK


A. Cannata.jpg

Dr. Antonio Cannata
London, UK


This podcast will discuss the most recent and serendipitous revolution in the field of Heart Failure, the SGLT2-inhibitors, their indications and future perspectives. Prof Rosano, interviewed by Dr Cannata, will drive through the most recent evidence supporting the use of SGLT2-i in patients with heart failure. Let's see whether an apple a day truly keeps the doctor away.


January 2022

Medical treatment for heart failure. News and controversies from 2021 ESC heart failure Guidelines

Prof. Ewa A. Jankowska
Wroclaw, Poland



Mateusz Sokolski
Wroclaw, Poland


The podcast presents the news and controversies related to 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The discussion between co-author of the guidelines and member of HFA Young Committee covers the important clinical aspects of medical treatment of heart failure and co-morbidities taking into account some doubts coming from guidelines and gaps in evidence.

The content of this podcast reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.